Prescription drug data

Each calendar year, the board shall identify nine drugs and at least one insulin product under ORS 646A.694 that the board determines may create affordability challenges for the health care systems or high out-of-pocket costs for patients in this state. The Oregon Prescription Drug Price Transparency program provides the board with the list of prescription drugs for review submitted under ORS 646A.689 (2) and (6), and ORS 743.025. This page contains the data files under review by the board. The board strictly maintains the confidentiality of any information collected, used or relied upon for the review that is protected trade secret, confidential, or proprietary information, as defined in ORS 192.345.